NCT03066258View on ClinicalTrials.gov

Safety and Tolerability of RGX-314 (Investigational Product) Gene Therapy for Neovascular AMD Trial

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

March 29, 2017

Primary Completion Date

November 24, 2019

Study Completion Date

June 17, 2021

Conditions
Neovascular Age-related Macular DegenerationWet Age-related Macular Degeneration
Interventions
GENETIC

RGX-314

RGX-314 is a recombinant adeno-associated virus (AAV) gene therapy vector carrying a coding sequence for a soluble anti-VEGF protein

Trial Locations (8)

19104

Philadelphia location 1, Philadelphia

19107

Philadelphia location 2, Philadelphia

21287

Baltimore location, Baltimore

38138

Memphis location, Germantown

77030

Houston location, Houston

89502

Reno location, Reno

93103

Santa Barbara location, Santa Barbara

02114

Boston location, Boston

All Listed Sponsors
lead

REGENXBIO Inc.

INDUSTRY

NCT03066258 - Safety and Tolerability of RGX-314 (Investigational Product) Gene Therapy for Neovascular AMD Trial | Biotech Hunter | Biotech Hunter